Low Dose Naltrexone is inexpensive, off-patent, and therefore has no commercial sponsor for research. That is exactly why independent funding matters.
Low Dose Naltrexone occupies an unusual position in medicine. It is inexpensive, has a long safety record, is off-patent, and shows genuine promise across inflammatory and autoimmune conditions. That combination should make it a research priority. In practice it makes it commercially unattractive, because no company recoups the cost of trials on a generic.
The Funding Gap
Modern drug research is largely financed by the entity that will sell the drug. Remove the patent and the financing disappears with it — regardless of how promising the compound is. The LDN Research Trust exists to fill that gap through independent funding, clinician education, and coordination of research that would otherwise never be commissioned.
A treatment does not become unpromising because it stopped being profitable. It just becomes unstudied.
What LDN Is Being Studied For
- Autoimmune conditions including Crohn disease and multiple sclerosis
- Fibromyalgia and centrally mediated chronic pain
- Complex regional pain syndrome
- Chronic fatigue syndrome and post-viral conditions
- Adjunct supportive use in oncology settings
We prescribe LDN where the clinical picture supports it, most often for autoimmune disease and chronic pain. Our longer explanation of the mechanism and evidence is in our article on LDN for autoimmune conditions and chronic pain.
What Our Involvement Means
Dr. Fantasia is a member of the LDN Research Trust, which means participating in clinician education, contributing clinical experience, and supporting the charity's work. It also means access to a network of prescribers refining protocols against real outcomes rather than in isolation. You can read more on our LDN Research Trust page.
We are careful not to overstate the evidence. LDN is not a cure and it does not help everyone. It is an inexpensive, well-tolerated option that deserves proper study, and supporting that study is the point.
Wondering whether LDN fits your case?
Schedule a complimentary consultation. We will review whether the evidence supports trying it for your specific condition.
Schedule a ConsultationFrequently Asked Questions
- What is the LDN Research Trust?
- It is a charity that funds independent research into Low Dose Naltrexone, educates clinicians, and coordinates studies that commercial sponsors have no financial incentive to run because the drug is off-patent.
- Why does off-patent status matter for research?
- Drug trials are usually financed by the company that will sell the drug. Once a medication is generic, no company recovers that investment, so promising off-patent treatments frequently go unstudied regardless of their potential.
- Is LDN right for everyone with autoimmune disease or chronic pain?
- No. LDN is not a cure and does not help every patient. It is a low-cost, well-tolerated option worth considering in the right clinical context, which is what a consultation determines.
Dr. Molly Fantasia
Medical Director · Innovative Medical Associates
